NEW YORK (GenomeWeb News) – Mayo Clinic has acquired a non-exclusive license to Expression Pathology's patent for use in diagnosing systemic amyloidosis in formalin-fixed tissue.
Expression Pathology said today that Mayo Clinic will use the Liquid Tissue patent in a test using mass spectrometric analysis of formalin-fixed paraffin-embedded tissue. Mayo Clinic will offer the test worldwide through its Mayo Medical Laboratories reference laboratory.